 SOMERSET, N.J.--BUSINESS WIRE--Legend Biotech Corporation NASDAQ: LEGN Legend Biotech, a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, announced today the submission of a Marketing Authorisation Application MAA to the European Medicines Agency EMA seeking approval of ciltacabtagene autoleucel cilta-cel for the treatment of patients with relapsed andor refractory multiple myeloma 